Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Palatin's MC4R Agonist Bremelanotide with GLP-1/GIP Tirzepatide Hits Ph 2 Goal
Details : Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for obesity.
Product Name : Vyleesi
Product Type : Peptide
Upfront Cash : Inapplicable
March 31, 2025
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
Details : Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for obesity.
Product Name : Vyleesi
Product Type : Peptide
Upfront Cash : Inapplicable
February 06, 2025
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Type 2 Diabetic Nephropathy
Details : Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with Tirzepatide for the treatment of type 2 diabetic nephropathy.
Product Name : Vyleesi
Product Type : Peptide
Upfront Cash : Inapplicable
December 19, 2024
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
Details : Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for the treatment of obesity.
Product Name : Vyleesi
Product Type : Peptide
Upfront Cash : Inapplicable
December 06, 2024
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Palatin Completes Enrollment for Bremelanotide in Obesity Study
Details : Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with Tirzepatide for the treatment Obesity in 18-65 year old patients.
Product Name : Vyleesi
Product Type : Peptide
Upfront Cash : Inapplicable
October 31, 2024
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Palatin Starts Phase 2 Study of Bremelanotide with Tirzepatide for Obesity
Details : Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for the treatment of obesity.
Product Name : Vyleesi
Product Type : Peptide
Upfront Cash : Inapplicable
August 22, 2024
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bremelanotide Acetate,Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Palatin Initiates Phase 2 Study of Bremelanotide for Erectile Dysfunction
Details : Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with PDE5i for the treatment of erectile dysfunction.
Product Name : Vyleesi
Product Type : Peptide
Upfront Cash : Inapplicable
June 20, 2024
Lead Product(s) : Bremelanotide Acetate,Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Cosette Pharma
Deal Size : $171.0 million
Deal Type : Acquisition
Cosette Pharmaceuticals Acquires Vyleesi® from Palatin Technologies
Details : Cosette expands its women's health platform by acquiring Vyleesi (bremelanotide acetate), first as-needed treatment for premenopausal women with acquired generalized hypoactive sexual desire disorder.
Product Name : Vyleesi
Product Type : Peptide
Upfront Cash : $12.0 million
March 01, 2024
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Cosette Pharma
Deal Size : $171.0 million
Deal Type : Acquisition
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Palatin Receives FDA Clearance for Bremelanotide with Tirzepatide in Obesity Treatment
Details : PT-141 (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for the treatment of obesity.
Product Name : Vyleesi
Product Type : Peptide
Upfront Cash : Inapplicable
February 05, 2024
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Cosette Pharma
Deal Size : $171.0 million
Deal Type : Divestment
Palatin Completes Sale of Vyleesi to Cosette Pharmaceuticals for up to $171 mn
Details : Cosette expands its women's health platform through divestment by adding Vyleesi, the first approved as-needed treatment for premenopausal women with acquired hypoactive sexual desire disorder.
Product Name : Vyleesi
Product Type : Peptide
Upfront Cash : $12.0 million
February 01, 2024
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Cosette Pharma
Deal Size : $171.0 million
Deal Type : Divestment